GlobeNewsWire
04 Aug 2026, 20:49 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Immix Biopharma appointed a Chief Medical Officer who was later revealed to be a fugitive from a 2005 rape trial using a false identity. — This indicates a catastrophic failure in corporate governance and due diligence, severely damaging management credibility.
-0.80Pomerantz LLP is investigating Immix Biopharma for potential securities fraud and unlawful business practices related to the CMO appointment. — The threat of a class-action lawsuit creates legal liabilities and financial risk for the company.
-0.60Immix Biopharma's stock price dropped 14.15% on July 20, 2026, following the news of the CMO's arrest. — The immediate market reaction confirms a loss of investor confidence and a reduction in market capitalization.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities fraud investigation and class action lawsuit following the discovery that its CMO was a fugitive.
A class action lawsuit has been filed against the company.
A class action lawsuit has been filed against the company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
37m ago
